Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06350318 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

StatusRecruiting
PhasePhase 2
Started2024-04-19
View on ClinicalTrials.gov ↗

Amendment history

2026-02-03
Study Status v7
Re-verified, no change to tracked fields
2025-10-30
Study Status, Sponsor/Collaborators v6
Collaborators1 entry, revised
BeiGeneBeOne Medicines
2025-08-04
2 amendments v4-v5
2 re-verifications since 2025-04-16, no change to tracked fields
2025-01-22
Study Status, Sponsor/Collaborators v3
Start date2024-03-13→2024-04-19
Collaborators1 entry, revised
BeOne MedicinesBeiGene
2024-09-30
Study Status v2
Re-verified, no change to tracked fields
2024-04-19
Study Status, Arms and Interventions, Outcome Measures v1
Secondary endpoints7 to 2 entries
Complete Response (CR) Partial Response (PR) Best Response (BR) DurationEfficacy of ResponseZanubrutinib (DoR)and Rituximab TimeSafety toand nexttolerability anti-lymphomaof therapy Progressioncombination FreeZanubrutinib Survivaland (PFS) Overall Survival (OS)Rituximab
Primary endpoints2 entries, revised
Overall Response Rate: (ORR)Cohort A Overall Response Rate: (ORR)Cohort B
2024-04-01
Original filing
The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).
Trial Details
NCT Number NCT06350318
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators: BeOne Medicines
Conditions Follicular Lymphoma, Marginal Zone Lymphoma, B-Cell Lymphoma
Enrollment 43 participants
Start Date 2024-04-19
Primary Completion 2029-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-09-28